<DOC>
	<DOCNO>NCT00768300</DOCNO>
	<brief_summary>The ARTEMIS-IPF study conduct determine ambrisentan effective delay disease progression death participant idiopathic pulmonary fibrosis ( IPF ) , evaluate safety , evaluate effect development pulmonary hypertension , quality life , dyspnea ( shortness breath ) symptom participant population . Participants randomize 2:1 ratio receive ambrisentan placebo , respectively . Participation study 4 year , depend long would take enroll participant observe study event . After randomization , visit clinic take place every 3 month , laboratory procedure perform every month .</brief_summary>
	<brief_title>( ARTEMIS-IPF ) Randomized , Placebo-Controlled Study Evaluate Safety Effectiveness Ambrisentan IPF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Male female 40 80 year age Diagnosis IPF Honeycombing ( fibrosis lung ) highresolution computerise tomography ( HRCT ) scan less equal 5 % Willing able 2 right heart catheterization perform Willing monthly lab test monitor liver function Able perform 6 minute walk test ( indicated adequate physical function ) Must meet lung function requirement Normal liver function test Negative serum pregnancy test Willing use least 2 reliable method contraception Able understand willing sign inform consent form No restrictive lung disease ( usual interstitial pneumonia IPF ) No obstructive lung disease No recent active respiratory exacerbation No recent hospitalization IPF exacerbation No recent history alcohol abuse Chronic sildenafil ( drug class ) use pulmonary hypertension Chronic treatment certain medication IPF within 30 day randomization No serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>interstitial lung disease</keyword>
	<keyword>ambrisentan</keyword>
</DOC>